How profitable is it to purchase finished formulations from China

How profitable is it to purchase finished formulations from China
The pharmaceutical agency industry is a dream industry for many small and medium-sized pharmaceutical companies, but the threshold of this industry is not low, many small and medium-sized enterprises want to do but dare not do due to capital and qualification problems, there are also some capital and qualifications but afraid to take risks, because once the unsuccessful investment will be reduced to nothing, of course, the biggest reason is not to know how the development prospects of pharmaceutical agents.
At present, China's biomedical industry is in the transition period of policy change, power change, quality change, and the successive conversion of the old and new dynamics of the industry is accelerating. This is also the mainstream trend of the current Chinese pharmaceutical market. Of course, in line with the development of the pharmaceutical market trend also harbors a problem that can not be ignored: innovative drugs can not be the turn of agents, good generic drugs and into the centralized procurement, coupled with the centralized procurement of local finished formulations, making the original high in the preparation varieties almost a net, the market is less and less truly competitive products.
Pharmaceutical companies to regulate the road how to go?
What is pharmaceutical compliance and what are the criteria for compliance? Compliance in a narrow sense means compliance with relevant national laws and regulations and compliance with the industry’s internal competition guidelines. The quality of pharmaceutical companies on the market is uneven, but the law of survival of the fittest is universal, so the standardization of pharmaceutical companies is inevitable.
There are four main trade barriers to pharmaceutical preparations: financial barriers, technical barriers, customer barriers and industry access barriers. Pharmaceutical trade barriers are high is justifiable, because it is known that drug safety can not be sloppy, so countries around the world in the pharmaceutical industry access, production, operation, sales and other aspects of the development of a series of standardized laws and regulations to strengthen the regulation of the pharmaceutical industry and supervision. So for the time being, the trade barriers in the API industry are still relatively high, and the previous era of winning by price war has passed.
In order to put the pharmaceutical market back on track, the original marketing-based business model is gradually withdrawn and replaced by a new pharmaceutical trade model, which is a way to reduce the independent publicity costs of pharmaceutical enterprises by integrating various suppliers of APIs and preparations in the market and build a bridge between the Chinese pharmaceutical market and the global pharmaceutical market. This is exactly the original intention of the establishment of Pharmacare and the company's business philosophy, Pharmacare is exactly such a comprehensive pharmaceutical trade service provider, since it is a comprehensive service provider that is different from the general pharmaceutical enterprises, the company has established an excellent reputation in China and even the world pharmaceutical field after years of operation, Pharmacare has established cooperative relationships with many famous Chinese pharmaceutical suppliers, not only that, Pharmacare can also provide a full range of pharmaceutical services from new drug Based on this, Pharmacare is the first-class integrated pharmaceutical trade service provider in China.